The immune exhaustion paradox: activated functionality during chronic bacterial infections

Area of Science:

• Immunology
• Microbiology
• Oncology

Background:

• Immune checkpoints, including CTLA-4 and PD-1, are key regulators of T and myeloid cell activity in chronic viral infections and cancer.
• Their role in chronic bacterial infections, especially Mycobacterium tuberculosis (Mtb), is less understood.
• The cytokine milieu significantly influences co-inhibitory molecule expression in tuberculosis.

Purpose of the Study:

• To explore the role of immune checkpoints in chronic bacterial infections, specifically tuberculosis.
• To investigate how the cytokine microenvironment affects co-inhibitory molecule expression in Mtb infection.
• To examine the intersection of immune checkpoint inhibitors (ICIs) used in cancer therapy and their potential implications for tuberculosis.

Main Methods:

• Analysis of cytokine-mediated regulation of co-inhibitory molecule expression in the context of Mtb antigens.
• Review of literature on the role of immune checkpoints in chronic inflammation and infection.
• Discussion of the potential impact of cancer immunotherapies (ICIs) on tuberculosis reactivation.

Main Results:

• Interleukin-12 (IL-12) can enhance co-inhibitory molecule expression in the presence of Mtb antigens, while maintaining CD4+ T cell effector and memory phenotypes.
• Co-inhibitory molecule expression is vital for controlling inflammation in chronic bacterial infections.
• Rare reports suggest a potential link between ICIs used in cancer therapy and tuberculosis reactivation.

Conclusions:

• The cytokine microenvironment, particularly IL-12, modulates immune checkpoint expression in tuberculosis.
• Immune checkpoint molecules act as a protective "brake" in chronic bacterial infections, contrasting with their role in cancer-induced exhaustion.
• Understanding these mechanisms is crucial for managing tuberculosis and potential side effects of immunotherapies.